Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea
Introduction Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D)...
Gespeichert in:
| Veröffentlicht in: | Advances in therapy 2024-06, Vol.41 (6), p.2253-2266 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2266 |
|---|---|
| container_issue | 6 |
| container_start_page | 2253 |
| container_title | Advances in therapy |
| container_volume | 41 |
| creator | Lacy, Brian E. Gagnon-Sanschagrin, Patrick Heimanson, Zeev Bungay, Rebecca Bellefleur, Remi Guérin, Annie Bumpass, Brock Borroto, Danellys Joseph, George Dashputre, Ankur A. |
| description | Introduction
Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA.
Methods
Adult patients (18–64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics
®
Plus database (10/01/2015–12/31/2021) and classified into two mutually exclusive cohorts (i.e., rifaximin and eluxadoline). Index date was the date of rifaximin or eluxadoline initiation. Entropy-balanced baseline characteristics, TFI (periods of ≥ 30 consecutive days without IBS-D treatment), and healthcare costs were reported. Healthcare costs were compared between cohorts using mean cost differences.
Results
There were 7094 and 2161 patients in the rifaximin and eluxadoline cohorts, respectively. After balancing, baseline characteristics (mean age 44.1 years; female 72.4%) were similar between cohorts. A higher proportion of patients treated with rifaximin achieved a TFI of ≥ 30 days (76.2% vs. 66.7%), ≥ 60 days (67.0% vs. 47.0%), ≥ 90 days (61.0% vs. 38.7%), ≥ 180 days (51.7% vs. 31.0%), and ≥ 240 days (47.7% vs. 27.9%) compared to eluxadoline. Among patients with a TFI ≥ 30 days, mean TFI durations were 8.3 and 6.0 months for the rifaximin and eluxadoline cohorts. Mean all-cause healthcare costs were lower for rifaximin vs. eluxadoline ($18,316 vs. $23,437;
p
= 0.008), primarily driven by pharmacy costs ($7348 vs. $10,250;
p
|
| doi_str_mv | 10.1007/s12325-024-02832-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11133130</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3039236086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-6d6947fdfa75aa411f1282186df86d4263f546e4cdc1c2fd51e202ba3f2c1ef93</originalsourceid><addsrcrecordid>eNp9kctuFDEQRS0EIkPgB1ggL9mY-NFPNqgTJmGkCBAEwc7yuMszjrrtxvZMkj_iMzF0GMGGxVUt6tStUl2EnjP6ilFan0TGBS8J5UVWIzi5fYAWrKlKksUfogWtC0a4aL4doScxXlPKaV02j9GRaCrW1pwu0I-rACqN4BI5DwB45RKEvRpe4w6_93sYcDdNwSu9xcnjLkaI0boN_gRqIF99GHp8cMBLY0AnuweXKaxcj5faOz9ajVfjpHTC3ejz8EeVbOYjvrFpi1ch2KTWA-BTf5MXfr5zffAjzN23VoWwBfUUPTJqiPDsvh6jL-fLq7N35PLDxeqsuyRatE0iVV-1RW16o-pSqYIxw3jD81N6k1XwSpiyqKDQvWaam75kwClfK2G4ZmBacYzezL7Tbj1Cr_OdQQ1yCnZU4U56ZeW_HWe3cuP3kjEmBBM0O7y8dwj--w5ikqONGoZBOfC7KDPSclHRpsoon1EdfIwBzGEPo_JXxnLOWOaM5e-M5W0eevH3hYeRP6FmQMxAzC23gSCv_S64_LX_2f4ES963KQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3039236086</pqid></control><display><type>article</type><title>Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea</title><source>SpringerNature Journals</source><creator>Lacy, Brian E. ; Gagnon-Sanschagrin, Patrick ; Heimanson, Zeev ; Bungay, Rebecca ; Bellefleur, Remi ; Guérin, Annie ; Bumpass, Brock ; Borroto, Danellys ; Joseph, George ; Dashputre, Ankur A.</creator><creatorcontrib>Lacy, Brian E. ; Gagnon-Sanschagrin, Patrick ; Heimanson, Zeev ; Bungay, Rebecca ; Bellefleur, Remi ; Guérin, Annie ; Bumpass, Brock ; Borroto, Danellys ; Joseph, George ; Dashputre, Ankur A.</creatorcontrib><description>Introduction
Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA.
Methods
Adult patients (18–64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics
®
Plus database (10/01/2015–12/31/2021) and classified into two mutually exclusive cohorts (i.e., rifaximin and eluxadoline). Index date was the date of rifaximin or eluxadoline initiation. Entropy-balanced baseline characteristics, TFI (periods of ≥ 30 consecutive days without IBS-D treatment), and healthcare costs were reported. Healthcare costs were compared between cohorts using mean cost differences.
Results
There were 7094 and 2161 patients in the rifaximin and eluxadoline cohorts, respectively. After balancing, baseline characteristics (mean age 44.1 years; female 72.4%) were similar between cohorts. A higher proportion of patients treated with rifaximin achieved a TFI of ≥ 30 days (76.2% vs. 66.7%), ≥ 60 days (67.0% vs. 47.0%), ≥ 90 days (61.0% vs. 38.7%), ≥ 180 days (51.7% vs. 31.0%), and ≥ 240 days (47.7% vs. 27.9%) compared to eluxadoline. Among patients with a TFI ≥ 30 days, mean TFI durations were 8.3 and 6.0 months for the rifaximin and eluxadoline cohorts. Mean all-cause healthcare costs were lower for rifaximin vs. eluxadoline ($18,316 vs. $23,437;
p
= 0.008), primarily driven by pharmacy costs ($7348 vs. $10,250;
p
< 0.001). In a simulated health plan of one million commercially insured lives, initiating 50% of patients on rifaximin instead of eluxadoline resulted in total cost savings of $2.1 million per year or $0.18 per-member-per-month.
Conclusions
This real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline.</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-024-02832-x</identifier><identifier>PMID: 38619720</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Cardiology ; Endocrinology ; Internal Medicine ; Medicine ; Medicine & Public Health ; Oncology ; Original Research ; Pharmacology/Toxicology ; Rheumatology</subject><ispartof>Advances in therapy, 2024-06, Vol.41 (6), p.2253-2266</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c398t-6d6947fdfa75aa411f1282186df86d4263f546e4cdc1c2fd51e202ba3f2c1ef93</cites><orcidid>0000-0001-7235-3292</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-024-02832-x$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-024-02832-x$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38619720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lacy, Brian E.</creatorcontrib><creatorcontrib>Gagnon-Sanschagrin, Patrick</creatorcontrib><creatorcontrib>Heimanson, Zeev</creatorcontrib><creatorcontrib>Bungay, Rebecca</creatorcontrib><creatorcontrib>Bellefleur, Remi</creatorcontrib><creatorcontrib>Guérin, Annie</creatorcontrib><creatorcontrib>Bumpass, Brock</creatorcontrib><creatorcontrib>Borroto, Danellys</creatorcontrib><creatorcontrib>Joseph, George</creatorcontrib><creatorcontrib>Dashputre, Ankur A.</creatorcontrib><title>Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Introduction
Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA.
Methods
Adult patients (18–64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics
®
Plus database (10/01/2015–12/31/2021) and classified into two mutually exclusive cohorts (i.e., rifaximin and eluxadoline). Index date was the date of rifaximin or eluxadoline initiation. Entropy-balanced baseline characteristics, TFI (periods of ≥ 30 consecutive days without IBS-D treatment), and healthcare costs were reported. Healthcare costs were compared between cohorts using mean cost differences.
Results
There were 7094 and 2161 patients in the rifaximin and eluxadoline cohorts, respectively. After balancing, baseline characteristics (mean age 44.1 years; female 72.4%) were similar between cohorts. A higher proportion of patients treated with rifaximin achieved a TFI of ≥ 30 days (76.2% vs. 66.7%), ≥ 60 days (67.0% vs. 47.0%), ≥ 90 days (61.0% vs. 38.7%), ≥ 180 days (51.7% vs. 31.0%), and ≥ 240 days (47.7% vs. 27.9%) compared to eluxadoline. Among patients with a TFI ≥ 30 days, mean TFI durations were 8.3 and 6.0 months for the rifaximin and eluxadoline cohorts. Mean all-cause healthcare costs were lower for rifaximin vs. eluxadoline ($18,316 vs. $23,437;
p
= 0.008), primarily driven by pharmacy costs ($7348 vs. $10,250;
p
< 0.001). In a simulated health plan of one million commercially insured lives, initiating 50% of patients on rifaximin instead of eluxadoline resulted in total cost savings of $2.1 million per year or $0.18 per-member-per-month.
Conclusions
This real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline.</description><subject>Cardiology</subject><subject>Endocrinology</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Rheumatology</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kctuFDEQRS0EIkPgB1ggL9mY-NFPNqgTJmGkCBAEwc7yuMszjrrtxvZMkj_iMzF0GMGGxVUt6tStUl2EnjP6ilFan0TGBS8J5UVWIzi5fYAWrKlKksUfogWtC0a4aL4doScxXlPKaV02j9GRaCrW1pwu0I-rACqN4BI5DwB45RKEvRpe4w6_93sYcDdNwSu9xcnjLkaI0boN_gRqIF99GHp8cMBLY0AnuweXKaxcj5faOz9ajVfjpHTC3ejz8EeVbOYjvrFpi1ch2KTWA-BTf5MXfr5zffAjzN23VoWwBfUUPTJqiPDsvh6jL-fLq7N35PLDxeqsuyRatE0iVV-1RW16o-pSqYIxw3jD81N6k1XwSpiyqKDQvWaam75kwClfK2G4ZmBacYzezL7Tbj1Cr_OdQQ1yCnZU4U56ZeW_HWe3cuP3kjEmBBM0O7y8dwj--w5ikqONGoZBOfC7KDPSclHRpsoon1EdfIwBzGEPo_JXxnLOWOaM5e-M5W0eevH3hYeRP6FmQMxAzC23gSCv_S64_LX_2f4ES963KQ</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Lacy, Brian E.</creator><creator>Gagnon-Sanschagrin, Patrick</creator><creator>Heimanson, Zeev</creator><creator>Bungay, Rebecca</creator><creator>Bellefleur, Remi</creator><creator>Guérin, Annie</creator><creator>Bumpass, Brock</creator><creator>Borroto, Danellys</creator><creator>Joseph, George</creator><creator>Dashputre, Ankur A.</creator><general>Springer Healthcare</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7235-3292</orcidid></search><sort><creationdate>20240601</creationdate><title>Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea</title><author>Lacy, Brian E. ; Gagnon-Sanschagrin, Patrick ; Heimanson, Zeev ; Bungay, Rebecca ; Bellefleur, Remi ; Guérin, Annie ; Bumpass, Brock ; Borroto, Danellys ; Joseph, George ; Dashputre, Ankur A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-6d6947fdfa75aa411f1282186df86d4263f546e4cdc1c2fd51e202ba3f2c1ef93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiology</topic><topic>Endocrinology</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lacy, Brian E.</creatorcontrib><creatorcontrib>Gagnon-Sanschagrin, Patrick</creatorcontrib><creatorcontrib>Heimanson, Zeev</creatorcontrib><creatorcontrib>Bungay, Rebecca</creatorcontrib><creatorcontrib>Bellefleur, Remi</creatorcontrib><creatorcontrib>Guérin, Annie</creatorcontrib><creatorcontrib>Bumpass, Brock</creatorcontrib><creatorcontrib>Borroto, Danellys</creatorcontrib><creatorcontrib>Joseph, George</creatorcontrib><creatorcontrib>Dashputre, Ankur A.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lacy, Brian E.</au><au>Gagnon-Sanschagrin, Patrick</au><au>Heimanson, Zeev</au><au>Bungay, Rebecca</au><au>Bellefleur, Remi</au><au>Guérin, Annie</au><au>Bumpass, Brock</au><au>Borroto, Danellys</au><au>Joseph, George</au><au>Dashputre, Ankur A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>41</volume><issue>6</issue><spage>2253</spage><epage>2266</epage><pages>2253-2266</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction
Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA.
Methods
Adult patients (18–64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics
®
Plus database (10/01/2015–12/31/2021) and classified into two mutually exclusive cohorts (i.e., rifaximin and eluxadoline). Index date was the date of rifaximin or eluxadoline initiation. Entropy-balanced baseline characteristics, TFI (periods of ≥ 30 consecutive days without IBS-D treatment), and healthcare costs were reported. Healthcare costs were compared between cohorts using mean cost differences.
Results
There were 7094 and 2161 patients in the rifaximin and eluxadoline cohorts, respectively. After balancing, baseline characteristics (mean age 44.1 years; female 72.4%) were similar between cohorts. A higher proportion of patients treated with rifaximin achieved a TFI of ≥ 30 days (76.2% vs. 66.7%), ≥ 60 days (67.0% vs. 47.0%), ≥ 90 days (61.0% vs. 38.7%), ≥ 180 days (51.7% vs. 31.0%), and ≥ 240 days (47.7% vs. 27.9%) compared to eluxadoline. Among patients with a TFI ≥ 30 days, mean TFI durations were 8.3 and 6.0 months for the rifaximin and eluxadoline cohorts. Mean all-cause healthcare costs were lower for rifaximin vs. eluxadoline ($18,316 vs. $23,437;
p
= 0.008), primarily driven by pharmacy costs ($7348 vs. $10,250;
p
< 0.001). In a simulated health plan of one million commercially insured lives, initiating 50% of patients on rifaximin instead of eluxadoline resulted in total cost savings of $2.1 million per year or $0.18 per-member-per-month.
Conclusions
This real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>38619720</pmid><doi>10.1007/s12325-024-02832-x</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-7235-3292</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0741-238X |
| ispartof | Advances in therapy, 2024-06, Vol.41 (6), p.2253-2266 |
| issn | 0741-238X 1865-8652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11133130 |
| source | SpringerNature Journals |
| subjects | Cardiology Endocrinology Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology |
| title | Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A42%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment-Free%20Interval:%20A%20Novel%20Approach%20to%20Assessing%20Real-World%20Treatment%20Effectiveness%20and%20Economic%20Impact%20Among%20Patients%20with%20Irritable%20Bowel%20Syndrome%20with%20Diarrhea&rft.jtitle=Advances%20in%20therapy&rft.au=Lacy,%20Brian%20E.&rft.date=2024-06-01&rft.volume=41&rft.issue=6&rft.spage=2253&rft.epage=2266&rft.pages=2253-2266&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-024-02832-x&rft_dat=%3Cproquest_pubme%3E3039236086%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3039236086&rft_id=info:pmid/38619720&rfr_iscdi=true |